Hepatology News

The U.S. Supreme Court ruled 5-4 on Thursday that members of the Sackler family cannot be protected from future lawsuits for their roles in the opioid epidemic.

Researchers have developed a data-driven, systematic approach for classification of the most potentially hepatotoxic medications based on incidence rates of severe acute liver injury, rather than published case report counts.

A two-dose series of a hepatitis B vaccine with a CpG adjuvant resulted in a more than 90% response rate among health care workers previously classified as nonresponders, researchers found.

The concept of delayed gratification has been ingrained in us throughout medical school and residency. This mentality can sometimes lead to explosive spending as an attending when one enjoys a significant salary boost.

Interim analyses of two phase 2b studies of volixibat support its use as potential treatment for patients with primary biliary cholangitis and primary sclerosing cholangitis, according to a press release from Mirum Pharmaceuticals.

The Council for Medical Specialty Societies, or CMSS, announced the launch of a new initiative that aims to reduce clinicians’ reliance on race in clinical decision-making and patient harms.

Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research.

Survodutide has an “acceptable safety profile” in patients with metabolic dysfunction-associated steatohepatitis with compensated and decompensated cirrhosis, with no dose reduction needed based on pharmacokinetics, according to data.

New survey results from the AMA illustrate the burden of prior authorization, with many physicians reporting that it leads to serious patient harms, delays care, reduces work productivity and more.

In a Healio video exclusive, Mitchell L. Shiffman, MD, reports that U.S. patients with severe alcohol-associated hepatitis treated with larsucosterol experienced a “statistically significant” reduction in 90-day mortality — more than 50%.